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ABSTRACT
Objectives: The aim of this study is to evaluate the results of advanced stage (stage IIIB-IVB) ovarian cancer (OC) patients 
with intestinal metastasis, and to investigate the factors that affect survival.
Material and methods: Patients who underwent cytoreductive surgery (CS) for FIGO stage IIIB-IVB OC with metastasis 
in the intestinal system, at Tepecik Research and Treatment Hospital between 2008–2014, were analyzed retrospectively. 
Patients with borderline ovarian tumor; those who had previously undergone radiation therapy and/or hysterectomy 
and patients having secondary or tertiary cytoreduction were excluded and 49 patients were included and analyzed in 
this study. Hysterectomy, bilateral salpingo-oopherectomy, pelvic and para-aortic lymph node sampling, resection of 
bulky lymph nodes and omentectomy were performed. Optimal cytoreduction was accepted as that which left residual 
tumor ≤ 1 cm maximum size.
Results: The risk factors affecting OS interval were investigated according to Cox’ regression analysis. Optimality of the 
primary CS (p = 0.008 and HR = 5.202) and cancer stage (p = 0.016 and HR = 6.083) were found to be statistically significant 
factors.
Conclusions: Achieving optimal CS is the most important aim for the general surgeon carrying out an intestinal resection 
procedure. Although resection procedures are superior in providing the desired optimal results when compared to exci-
sion surgery, their higher complication rates and subsequent lower quality of life must be taken into consideration when 
choosing either resection or excision methods; surgical intervention should always be kept to the minimum possible.
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INTRODUCTION
Ovarian cancer (OC), being responsible for 40% of all 
gynecologic cancers in women, is the most lethal gyne-
cological malignity [1]. OC generally expands through the 
abdominal cavity before becoming symptomatic and is 
most often diagnosed when local metastatic disease has 
already taken hold (International Federation of Gynecology 
and Obstetrics [FIGO] stage III and IV) [2, 3].
The most important prognostic factors in advanced 
stage OC are the stage of the disease and the ability to 
perform optimal cytoreductive surgery (CS) during primary 
surgery [4, 5]. Indeed, in advanced stage OC, the standard 
treatment with the best oncologic outcomes is primary CS 
followed by adjuvant chemotherapy (CT) [3, 6]. The objec-
tive of primary debulking surgery is to achieve maximum 
cytoreduction [7]. CS comprises hysterectomy, bilateral 
salpingo-oopherectomy, omentectomy and complete re-
section of macroscopic peritoneal implants [5]. Because of 
its anatomic proximity to the woman’s pelvic organs and 
the tendency of OC to spread, rectosigmoid resection is 
the most commonly performed intestinal surgery proce-
dure in a successful optimal cytoreduction [5]. If the tumor 
has infiltrated the pelvic sidewalls, en bloc resection of the 
tumor, uterus, adnexa and rectosigmoid is performed [5].
CS appears to be associated with a higher rate of intra-
operative and early postoperative complications, such as 
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bleeding, anastomotic leak and infection. In selected cases, 
ostomy is needed, which inevitably leads to a remarkable 
deterioration in the quality of the patient’s life. At this point, 
it becomes debatable whether the advantages of optimal 
cytoreduction during primary treatment are sufficient to 
compensate for the risks brought by this extensive surgery.
The aim of this study is to evaluate the results of ad-
vanced stage (stage IIIB-IVB) OC patients with intestinal 
metastasis; and to investigate the factors that affect survival. 
MATERIAL AND METHODS
Patients who underwent CS for FIGO stage IIIB-IVB OC 
with metastasis in the intestinal system, at Tepecik Research 
and Treatment Hospital between 2008–2014, were analyzed 
retrospectively. Patients with borderline ovarian tumor, 
a prior history of radiation therapy, prior hysterectomy and 
secondary or tertiary cytoreduction were excluded from the 
study. So totally 49 patients were included and analyzed in 
this study. The study group’s surgical and pathology reports 
were evaluated in terms of disease-related features, surgi-
cal and postoperative factors, and long-term results. The 
study was approved by the local ethics committee at our 
institution.
The patients received a liquid diet and a mechanical 
bowel preparation was used one day prior to surgery. All sur-
gical operations were carried out by experienced surgeons 
in the fields of general and gynecological oncologic surgery. 
A vertical midline incision was preferred in all patients for 
ease of access during exploration of the abdomen and or-
gan resection. After entering the peritoneal cavity, ascites 
fluid was sampled if present; if not, peritoneal washing cytol-
ogy was taken. During exploration of the abdominal cavity, 
peritoneal surfaces, omentum, colon and small intestine, 
paracolic, pelvic, mesenteric and para-aortic sites were all 
examined systematically and palpated to find any suspicious 
lesions. Hysterectomy, bilateral salpingo-oopherectomy; 
pelvic and para-aortic lymph node sampling; resection of 
bulky lymph nodes and omentectomy were all performed. 
Optimal cytoreduction was considered to be a residual 
tumor size ≤ one cm maximum, in accordance with the 
definition given by the Gynecologic Oncology Group 2006.
Our female patients came for follow-up evaluations 
every three months for the first two years, every six months 
for the next three years and annually thereafter. Computed 
tomography or magnetic resonance imaging was performed 
annually. The only criterion for ending follow-up was the 
death of the patient.
Survival analysis was based on the Kaplan-Meier meth-
od, and the results were compared using a log-rank test. 
Disease-free survival (DFS) was measured as the time be-
tween the primary surgery and detection of the first recur-
rence or the latest observation. Overall survival (OS) was 
the time between initial treatment and death or the latest 
observation. For statistical analysis, we used the χ2 test and 
Student’s t-test for unpaired data. Cox’ regression analysis 
was used to determine factors affecting survival, presented 
as hazard ratios (HR) and 95% confidence intervals (CI). Data 
recording and statistical analyses were performed using 
SPSS (statistical package for the social sciences) software 
(version 17, SPSS, Inc, Chicago, IL). A p < 0.05 was considered 
to indicate statistical significance.
RESULTS
Clinical features of the patients are shown in Table 1. The 
mean patient age was 54.1 ± 10.6 and mean tumor size 
was 11.6 ± 5.6 cm. Six (12.2%) of the patients were sta- 
ge IIIB, 28 (57.1%) were stage IIIC and 15 (30.6%) were 
stage IVB. All patients underwent hysterectomy, bilateral 
salpingoophorectomy, pelvic paraaortic lymph node dis-
section and omentectomy as primary surgery. Hypertermic 
intraperitoneal chemotherapy (HIPEC) was administered to 
55.1% of the patients and 10.2% of the patients underwent 
appendectomy. Peritonectomy procedure was added to 
24.4% of the patients. Before surgery, 10.2% of patients 
received neoadjuvant CT. Adjuvant paclitaxel + carboplatin 
was administered to 98.0% of the patients and 14.3% of the 
patients received neoadjuvant CT. CT could not be given to 
one patient due to her medical status. 10.2% of the patients 
who underwent resection + end-to-end anastomosis also 
had ileum resection. The mean number of pelvic lymph 
nodes (PLN) removed was 21.1 ± 11.4 and the number of 
paraaortic lymph nodes (PaLN) was 19.0 ± 10.2. PLN involve-
Table 1. Clinical features of patients
n Percentage (%)
Intestinal surgery during primary operation
Tumor excision
Resection + ostomy
Resection + end to end anastomosis
 
7
34
8
 
14.3
69.4
16.3
Parts of intestinal surgery
Sigmoid colon, rectum
Right colon
Transvers colon
Ileum
 
40
4
3
2
 
81.6
8.2
6.1
4.1
Operation efficiency
Suboptimal
Optimal
 
15
34
 
30.6
69.4
Histological type
Epithelial cell
Germ cell
Sex-cord stromal tumor
 
46
2
1
 
93.9
4.1
2.0
Intestinal layer involvement
Serosa
Muscularis
Mucosa
 
38
7
4
 
77.6
14.3
8.2
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ment was seen in 36.7% of the patients with PaLN in 36.7% 
of the patients.
Survival time and recurrence rates according to the 
type of  intestinal surgery,  the intestinal layer invaded by 
the tumor, and the efficiency of the surgery are shown in 
Table 2. Survival curves according to intestinal surgery type, 
the intestinal layer invaded by the tumor and the efficien-
cy of surgery are shown in Figures 1, 2 and 3, respectively.
Risk factors affecting the OS interval were investigated 
according to Cox’ regression analysis. Optimality of the pri-
mary CS (p = 0.008 and HR = 5.202) and stage (p = 0.016 and 
HR = 6.083) were found to be statistically significant factors 
(Table 3).
Bladder laceration was seen in 6.7% of patients who 
underwent suboptimal surgery, and in 2.9% in patients 
whose surgery was optimal (p = 0.544). Ileus was observed 
in 13.3% of the patients who underwent suboptimal sur-
gery. In the optimal surgical group, anastomotic leakage 
developed in 5.9%, wound infection in 5.9% and cardiac 
arrest in 2.9% of the patients. There were no complications 
in the tumor excision group. However, in patients undergo-
ing resection + ostomy, ileus, anastomotic leakage, wound 
infection and cardiac arrest were seen at rates of 2.9%, 2.9%, 
2.9% and 2.9%, respectively. In patients who underwent 
resection + end-to-end anastomosis, ileus, anastomosis 
leakage and wound side infection occurred at 12.5%, 12.5% 
and 12.5%, respectively. 
42.8% of patients whose tumor was excised during their 
primary CS needed a repeat operation with a resection+ostomy 
procedure and 14.2% had a repeat tumor excision procedure. 
25% of the patients who underwent resection+end-to-end 
anastomosis, had a repeat resection+ostomy procedure, 
while 8.8 % of patients who had a resection+ostomy under-
went a repetition of resection+ostomy.
Table 2. Survival time and recurrence rates according to intestinal surgery type, intestinal layer invaded by tumor and efficiency of surgery
DFS; means (month) ± SD OS; means (month) ± SD Recurrence; n (%)
Intestinal operation
Tumor excision
Resection + ostomy
Resection + end-to-end anastomosis
(p = 0.072)
 13.3 ± 4.3
 18.3 ± 2.2
 25.5 ± 5.3
(p = 0.333)
 20.8 ± 5.1
 38.6 ± 6.6
 34.0 ± 3.5
(p = 0.064)
6 (85.7)
13 (38.2)
3 (37.5)
Intestinal layer involvement
Serosa
Muscularis
Mucosa
(p = 0.131)
 20.1 ± 2.0
 16.2 ± 2.6
 5.2 ± 0.8
(p = 0.221)
 39.3 ± 6.4
 19.3 ± 2.5
 7.0 ± 1.2
(p = 0.973)
17 (44.7)
3 (42.9)
2 (50.0)
Efficiency of surgery
Non-optimal
Optimal
(p = 0.004)
 12.1 ± 3.3
 21.9 ± 2.1
(p = 0.002)
 20.9 ± 7.1
 30.3 ± 2.6
(p = 0.158)
9 (60.0)
13 (38.2)
DFS — disease free survival; OS — overall survival; SD — standard deviation
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Figure 1A. Disease free survival (p = 0.072) and B. Overall survival curves (p = 0.333) according to the type of intestinal surgery performed during 
primary cytoreductive surgery 
540
Ginekologia Polska 2017, vol. 88, no. 10
www. journals.viamedica.pl/ginekologia_polska
DISCUSSION
Forty-nine patients who underwent surgery for stage 
IIIB–IVB OC with intestinal involvement were investigated 
in this retrospective study. The effects of the type of surgery 
and the success of optimal cytoreduction on the recur-
rence of DFS and OS were evaluated. A surgical approach 
to the gastrointestinal system is frequently required in OC 
surgery. Studies report the success of CS in stage II, III, and 
IV cancer cases as between 41% and 85% [8, 9]. In our study, 
the optimal cytoreduction rate in IIIB-IVB cases performed 
by a duo of general surgeon and gyneco-oncologist was 
found to be 74.2%.
In a study that evaluated intestinal resection and 
end-to-end anastomosis performed due to the spread of 
OC through the intestinal system, 48% of the patients dem-
onstrated DFS and median survival time was 32 months [10]. 
The report shows that 5% of patients needed a secondary 
colostomy, while 25% of patients underwent anterior re-
section and reanastomosis [10]. When looking at different 
types of surgery, we found no differences regarding DFS 
(p = 0.072), OS (p = 0.333) and recurrence rates (p = 0.064) 
between the tumor excision, resection + ostomy and resec-
tion + end-to-end anastomosis groups. However, there were 
differences in terms of complications. While there were no 
complications in the tumor excision group, 2.9% ileus and 
2.9% anastomotic leakage rates were reported in patients 
having resection + ostomy; and 12.5% ileus and 12.5% anas-
tomosis leakage were reported in patients who underwent 
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Figure 2A. Disease free survival (p = 0.131) and B. Overall survival (p = 0.221) curves according to tumor expansion over intestinal layers
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Figure 3A. Disease free survival (p = 0.004) and B. Overall survival (p = 0.002) curves according to the efficiency of primary cytoreductive surgery 
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Resection + end-to-end anastomosis. Of those patients who 
had a tumor excision during their primary CS, 42.8% under-
went a repetition using the resection+ostomy procedure; 
and 14.2% had a repeated tumor excision procedure. 25% 
of the patients who underwent resection+end-to-end anas-
tomosis had a repeated resection+ostomy procedure, while 
8.8 % of the patients having resection+ostomy underwent 
a repeated resection+ostomy.
Reports have shown that patients with a rectal invasion 
through the serosa and above the serosa layer have longer 
DFS intervals than patients with muscularis and mucosa lay-
er invasions; however, there is no significant difference with 
regard to the OS interval [10]. We calculated DFS intervals 
(p = 0.131) according to tumor presence in the serosa, mus-
cularis or mucosa layers as 20.1–16.2–5.2 months, respec-
tively; and OS intervals (p = 0.221) as 39.3–19.3–7.0 months, 
respectively.
In a metaanalysis of 6,685 patients, it was seen that 
an increase of 10% in CS enhanced the mean survival rate 
by 5.5% [11]. The mean OS interval for patients with a total 
resection was 72 months and for those with a residual tu-
mor 42 months [8]. 4.7% of patients who underwent opti-
mal cytoreduction and 60% of patients with a suboptimal 
cytoreduction had pelvic recurrence [9]. Patients without 
a residual tumor had longer DFS and OS intervals than pa-
tients with a residual tumor [12]. Another study showed 
no significant difference between the two groups (total 
rectosigmoid resection group and partial rectosigmoid re-
section group) regarding 5-years OS rates which were 48% 
and 52%, respectively [13]. Patients undergoing optimal 
cytoreduction had significantly longer OS and DFS intervals 
according to our study. However, there was no significant 
difference between the two groups regarding recurrence 
rates. Bladder laceration was seen in 6.7% of patients who 
underwent suboptimal surgery and in 2.9% of patients who 
underwent optimal surgery (p = 0.544). Ileus was observed 
in 13.3% of patients who underwent suboptimal surgery. 
5.9% anastomotic leakage, 5.9% wound infection and 2.9% 
cardiac arrest developed in the optimal surgery group.
The study had several limitations: first, its retrospec-
tive nature; secondly, its small sample size. Despite these 
limitations, our hospital is a tertiary center for gynecologic 
oncology in the Aegean region, and many patients visit 
our clinic from distant locations. Therefore, the similarity of 
demographic characteristics in the study population, avail-
ability of good follow-up data, and performance of surgeries 
by the same surgical team increased the validity of results 
and mitigated weaknesses.
CONCLUSIONS
Achieving optimal cytoreduction is the most impor-
tant aim for the general surgeon carrying out an intestinal 
resection procedure. Although resection procedures are 
superior in providing the desired optimal results when com-
pared to excision surgery, their higher complication rates 
and subsequent lower quality of life must be taken into 
consideration when choosing either resection or excision 
methods; surgical intervention should always be kept to the 
minimum possible. However, further studies are needed to 
clarify the exact role to be played by the general surgeon 
in this situation. 
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